The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit…
This session will explore the characteristics of cryopreserved platelets from laboratory studies, followed by the first presentation of the results from the CLIP-II clinical trial. The CLIP-II trial is a phase III multicentre blinded randomised controlled clinical non-inferiority trial of cryopreserved platelets versus conventional liquid-stored platelets for the management of surgical bleeding. In the first presentation, laboratory investigations of the functional qualities of cryopreserved platelets and their haemostatic capacity will be described. Production methods of cryopreserved platelets, management of an inventory of cryopreserved platelets and health economic considerations will also be discussed. The session will then move to presentation of the outcomes of the CLIP-II trial, with emphasis on how they may change transfusion practice, particularly for bleeding patients. Data from other trials will also be explored, which suggest cryopreserved platelets may be less effective than expected for indications such as correcting a low platelet count in non-bleeding patients. This will be the first time that the results of the CLIP-II trial are presented.
Learning Objectives
After attending this session, the audience will be able to describe the effects of cryopreservation on platelet morphology and phenotype
After attending this session, the audience will be able to compare the effects of cryopreservation on the haemostatic function of platelets with the characteristics of room-temperature stored platelets.
After attending this session, the audience will be able to identify how cryopreserved platelets can be used to manage platelet inventory in austere environments.
After attending this session, the audience will be able to describe the effectiveness of cryopreserved platelets for the treatment of bleeding in surgery and other indications, based on evidence from the CLIP-II trial and other clinical trials.
After attending this session, the audience will be able to describe the health economic considerations associated with production and use of cryopreserved platelets.
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
Purchasing this session will automatically provide ownership of all the individually purchasable attached CE products, regardless of their stated individual purchase restrictions.
AM24-ST-22-O: Cryopreserved Platelets: From Bench to Bedside (Enduring) Evaluation
In 2024, blood bank technologist shortages continue to challenge our field. One obvious, but often overlooked, solution is to deploy cutting-edge technology to supplement personnel…
Anesthetic and surgical techniques have greatly improved blood loss outcomes in patients undergoing surgery, especially in heart and liver transplantation, but substantial blood use and critical decision points remain…
As the concept of pre-hospital transfusion for trauma rapidly gains traction in the US, the essential role of blood bank leaders in developing these complex programs becomes ever more clear…
AABB Standards 5.30.2, 5.30.3, and 5.30.4 require that Rh negative women who are pregnant or who have been pregnant recently be considered for Rh Immune Globulin administration when the Rh type of the fetus/neonate is unknown or positive when tested for D or weak D…